What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call

Impact · against what's priced in

Fresenius Medical Care faces a significant earnings cliff in 2027 due to a projected €300-€350 million TDAPA headwind, coupled with a weakened 2026 outlook. Immediate pressure from inflationary costs exceeding previous guidance further degrades the near-term margin profile.

FMS−0.40

No priced-in read yet

In context

The company has introduced a substantial 2027 operating-income pressure of €300 million to €350 million from TDAPA and narrowed its 2026 operating-income growth outlook to potentially reach a negative mid-single-digit percentage rate.

Read from the article alone

• earnings
• guidance
• healthcare
• inflation
• FMS
• cost cutting
• dialysis
• germany
• reimbursement
• share repurchase
• united states